Small intestinal cancer, commonly referred to as duodenal cancer, small bowel cancer, or ileal cancer, is typically an adenocarcinoma (occasionally a sarcoma, lymphoma, or a carcinoid tumors) that begins in the main parts of the small intestine including the ileum, jejunum, and duodenum. The ileum, specifically, is first division of the small intestine that works to absorb vitamin B12 and salts that were not absorbed by the jejunum. This type of cancer is very rare with only 2 out of every 100,000 people being diagnosed in the USA per year. Individuals with familial adenomatous polyposis (FAP) have a very high risk of duodenal cancer, thus preemptive removal of the duodenum is common. Other risk factors include Crohn's Disease, irritable bowel syndrome, coeliac disease, and Peutz-Jegher's syndrome. Treatments include surgery, chemotherapy, radiation therapy, and biological therapy. There are four stages that determine the severity and location of small intestinal cancer.
Ileal Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Ileal Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 1151 products for the study of Ileal Cancer that can be applied to Chromatin Immunoprecipitation, Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.